Research Models

PDGF-APP(WT) (line I5)


Back to the Top

Species: Mouse
Genes: APP
Modification: APP: Transgenic
Disease Relevance: Alzheimer's Disease
Strain Name: B6.Cg-Tg(PDGFB-APP)5Lms/J
Genetic Background: (C57BL/6 x DBA/2)F2
Availability: The Jackson Lab: Stock# 004662; Cryopreserved

These transgenic mice express wild-type human APP under the control of the human PDGF-β promoter. They were generated as control mice for the J20 model. They express human APP in neurons throughout the brain, with maximal levels in the neocortex and hippocampus. No plaques were observed out to 24 months, but synaptophysin immunoreactivity decreases with age (Mucke et al., 2000).

Modification Details

APP-WT driven by the human PDGF-β promoter; an APP transgene with the Indiana mutation was converted to wild-type by PCR primer modification.

Phenotype Characterization

When visualized, these models will distributed over a 18 month timeline demarcated at the following intervals: 1mo, 3mo, 6mo, 9mo, 12mo, 15mo, 18mo+.


  • Tangles
  • Neuronal Loss

No Data


Not observed.

Neuronal Loss

Not observed.

Synaptic Loss

By 2-4 months of age, there is a decrease in synaptophysin-immunoreactive presynaptic terminals compared to nonTg controls. Synaptophysin immunoreactivity decreases further with age.

Last Updated: 09 Sep 2013


No Available Comments

Make a comment or submit a question

To make a comment you must login or register.


Research Models Citations

  1. J20 (PDGF-APPSw,Ind)

Paper Citations

  1. . High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000 Jun 1;20(11):4050-8. PubMed.

External Citations

  1. The Jackson Lab: Stock# 004662

Further Reading

No Available Further Reading